PHASE I-II TRIAL OF IMATINIB MESYLATE (GLEEVEC; STI571) IN TREATMENT OF RECURRENT OLIGODENDROGLIOMA AND MIXED OLIGOASTROCYTOMA. NORTH CENTRAL CANCER TREATMENT GROUP STUDY N0272 (ALLIANCE/NCCTG)

PURPOSE: To evaluate the pharmacokinetics and efficacy of imatinib in patients with recurrent oligodendroglial tumors. METHODS: Patients with progressive WHO grade II-III recurrent tumors after prior RT and chemotherapy were eligible. A phase I dose-escalation study was conducted for patients on enz...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Neurooncol
Main Authors: Jaeckle, Kurt A., Anderson, S K., Twohy, Erin L., Dixon, Jesse G., Giannini, Caterina, Jenkins, Robert, Egorin, Merrill J., Sarkaria, Jann N., Brown, Paul D., Flynn, P J., Schwerkoske, John, Buckner, Jan C., Galanis, Eva
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6717651/
https://ncbi.nlm.nih.gov/pubmed/31119479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-019-03194-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados